What is Inhibrx Biosciences, Inc.'s business segments — G&A?

Inhibrx Biosciences, Inc. (INBX) reported business segments — G&A of $5.71M in Q1 2026.

What does business segments — G&A mean?

This metric aggregates all general and administrative expenses, including personnel, legal, and corporate overhead. It represents the total cost of running the business operations and supporting the company's infrastructure. It is a key indicator of the company's operational burn rate and corporate cost structure.

Inhibrx Biosciences, Inc. INBX Business Segments — G&A

Similar metrics at other companies

BCAXReportable Segment — G&A

$12.74M+70.9%

VCYTReportable Segment — G&A

$23.68M-30.0%

RSIReportable Segment — G&A

$25.81M+32.0%

UPWKReportable Segment — G&A

$25.56M+11.4%

PCVXReportable Segment — G&A

$33.07M+1.3%

ABUSReportable Segment — G&A

$5.89M+1.0%

Other financials

Income statement

See full

Revenue--100%

Operating income-$30.9M+27.9%

Net income-$33.4M+22.8%

EPS (diluted)-$2.15+23.2%

Balance sheet

See full

Cash & equivalents$161.7M-25.3%

Total debt$180.9M+69.8%

Total equity-$21.0M-122%

Total assets$184.0M-24.2%

Cash flow

See full

Operating cash flow-$38.0M-5.9%

CapEx--100%

Free cash flow-$38.0M-5.9%

Valuation

See full

Market cap$1.4B+546%

Enterprise value$1.42B+1,233%

P/S1,073.7×-280×

Profitability

See full

Operating margin-10,386.5%-5,025pp

Net margin-10,773.5%-878,492pp

FCF margin-9,986.5%-4,727pp

Returns & leverage

See full

Return on equity-197.8%-2,158pp

Debt / equity13.4×+13.3×

Current ratio6.5×+1.3×

Where this comes from

Reported directly by Inhibrx Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inhibrx Biosciences, Inc.'s business segments — g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Inhibrx Biosciences, Inc.'s business segments — G&A?: Inhibrx Biosciences, Inc. (INBX) reported business segments — G&A of $5.71M in Q1 2026.
What does business segments — G&A mean?: This metric aggregates all general and administrative expenses, including personnel, legal, and corporate overhead. It represents the total cost of running the business operations and supporting the company's infrastructure. It is a key indicator of the company's operational burn rate and corporate cost structure.